2022
Oncologic outcomes of neoadjuvant chemotherapy in patients with micropapillary variant urothelial carcinoma of the bladder
Rahman S, Lokeshwar S, Syed J, Javier-Desloges J, Press B, Choksi A, Rajwa P, Pradere B, Ploussard G, Kim J, Monaghan T, Renzulli J, Shariat S, Leapman M. Oncologic outcomes of neoadjuvant chemotherapy in patients with micropapillary variant urothelial carcinoma of the bladder. Urologic Oncology Seminars And Original Investigations 2022, 41: 107.e1-107.e8. PMID: 36481253, DOI: 10.1016/j.urolonc.2022.09.008.Peer-Reviewed Original ResearchConceptsVariant urothelial carcinomaNeoadjuvant chemotherapySubset of patientsUrothelial carcinomaOverall survivalPathologic responseRadical cystectomyNAC useClinical stage II diseaseHospital-based registry studyNeoadjuvant platinum-based chemotherapyPathologic lymph node positivityCox proportional hazards modelNational Cancer DatabaseStage II diseaseLymph node positivityPathologic complete responsePlatinum-based chemotherapyKaplan-Meier analysisMultivariable logistic regressionAnalysis of patientsBladder urothelial carcinomaProportional hazards modelCT2 diseasePathologic upstaging
2021
Patient- and provider-level predictors of mortality among patients with metastatic renal cell carcinoma receiving oral anticancer agents.
Spees L, Dinan M, Jackson B, Baggett C, Wilson L, Greiner M, Kaye D, Zhang T, George D, Scales C, Pritchard J, Leapman M, Gross C, Wheeler S. Patient- and provider-level predictors of mortality among patients with metastatic renal cell carcinoma receiving oral anticancer agents. Journal Of Clinical Oncology 2021, 39: 116-116. DOI: 10.1200/jco.2020.39.28_suppl.116.Peer-Reviewed Original ResearchMetastatic renal cell carcinomaOral anti-cancer agentsPatients' clinical characteristicsProvider-level factorsCause mortalityRenal cell carcinomaClinical characteristicsHazard ratioMetastatic diagnosisCell carcinomaState cancer registry dataCox proportional hazards modelProvider-level predictorsLower overall survivalOral anticancer agentsCancer registry dataReal-world populationProportional hazards modelSkilled nursing facilitiesProvider Enumeration SystemAnti-cancer agentsIndex dateOverall survivalPatient demographicsBlack patients
2019
Associations of rurality and disease outcomes in urologic malignancies.
Abello A, Casilla-Lennon M, Kenney P, Leapman M. Associations of rurality and disease outcomes in urologic malignancies. Journal Of Clinical Oncology 2019, 37: 661-661. DOI: 10.1200/jco.2019.37.7_suppl.661.Peer-Reviewed Original ResearchCancer-specific deathAssociation of ruralityUrologic malignanciesKidney cancerPoor cancer-specific survivalCox proportional hazards modelRural statusRural countiesCancer-specific survivalEnd Results (SEER) databaseProportional hazards modelPopulation-level dataDefinitive treatmentRural patientsGenitourinary malignanciesTestis cancerUrologic cancersWorse outcomesCancer incidenceDisease PDisease outcomeUrological cancersMultivariable regressionWhite raceOutcome data
2016
Application of a Prognostic Gleason Grade Grouping System to Assess Distant Prostate Cancer Outcomes
Leapman MS, Cowan JE, Simko J, Roberge G, Stohr BA, Carroll PR, Cooperberg MR. Application of a Prognostic Gleason Grade Grouping System to Assess Distant Prostate Cancer Outcomes. European Urology 2016, 71: 750-759. PMID: 27940155, DOI: 10.1016/j.eururo.2016.11.032.Peer-Reviewed Original ResearchConceptsRisk of PCSMGleason grade groupBone metastasesProstate Strategic Urologic Research Endeavor (CaPSURE) registryGroup ICox proportional hazards modelGrade groupBone metastatic progressionGrade group IPrimary androgen deprivationPrognostic grade groupingKaplan-Meier methodProstate cancer outcomesProportional hazards modelGroup VProstate cancer pathologyNondefinitive therapyDefinitive therapyConservative managementUnadjusted riskAndrogen deprivationGleason sumGleason scoreCancer outcomesGrouping systemRelationship of phosphodiesterase type 5 inhibitor to biochemical recurrence after definitive therapy for prostate cancer.
Leapman M, Cowan J, Nguyen H, Porten S, Cooperberg M, Carroll P. Relationship of phosphodiesterase type 5 inhibitor to biochemical recurrence after definitive therapy for prostate cancer. Journal Of Clinical Oncology 2016, 34: 119-119. DOI: 10.1200/jco.2016.34.2_suppl.119.Peer-Reviewed Original ResearchPhosphodiesterase type 5 inhibitorsBiochemical recurrenceType 5 inhibitorsProstate cancerUse of PDE5iMedian age 61 yearsMedian age 69 yearsProstate Strategic Urologic Research EndeavorRisk of BCRCox proportional hazards modelAndrogen deprivation therapyAge 61 yearsAge 69 yearsKaplan-Meier methodSexual function scoresCohort of menProportional hazards modelDeprivation therapyPrescription complianceDefinitive therapyTime-dependent useDefinitive treatmentDisease recurrenceClinical evidenceBaseline useExternal validation of a prognostic Gleason grade classification system.
Leapman M, Cowan J, Roberge G, Eltemamy M, Simko J, Carroll P, Cooperberg M. External validation of a prognostic Gleason grade classification system. Journal Of Clinical Oncology 2016, 34: 123-123. DOI: 10.1200/jco.2016.34.2_suppl.123.Peer-Reviewed Original ResearchProstate cancer-specific mortalityRisk of recurrenceGleason grade groupRadical prostatectomyAdjusted pairwise comparisonsGrade groupUCSF cohortGrade diseaseGleason 4Metastatic progressionCox proportional hazards modelGleason classification systemGrade classification systemImmediate radical prostatectomyCancer-specific mortalityAcademic referral centerHigh-grade diseaseIndependent prognostic abilityProportional hazards modelConsecutive PSA valuesDiscrimination of outcomesGleason grading systemGleason grade 3Salvage treatmentReferral center